Just a year ago, Novo Nordisk was a symbol of the diabetes and obesity revolution - its shares were one of the fastest-growing names on the global markets, reaching a peak capitalisation of approximately $615 billion in June 2024. Since then, the share price has fallen by roughly 60%, dropping the market value by a drastic US$380 billion. How will increasing competition, legal and regulatory pressure or a new CEO affect the company's strategy? Is this a crisis moment or does it open up a unique entry point for long-term investors?

Top points of the analysis

• A 60% drop: Since the all-time high in mid-2024, Novo Nordisk shares have fallen by around 60%, equivalent to a market value loss of around USD 375-395 billion. Just after the last profit warning, it disappeared from the stock market in one day USD 70 billion.
• Double downgrade: The company cut its revenue growth estimate for the second time this year to 8-14 % (up from 13-21%) and operating profit growth to 10-16 % (from 16-24%), which…